10173 related articles for article (PubMed ID: 1382457)
1. High level expression on a chimeric anti-ganglioside GD2 antibody: genomic kappa sequences improve expression in COS and CHO cells.
Fouser LA; Swanberg SL; Lin BY; Benedict M; Kelleher K; Cumming DA; Riedel GE
Biotechnology (N Y); 1992 Oct; 10(10):1121-7. PubMed ID: 1382457
[TBL] [Abstract][Full Text] [Related]
2. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice.
Zeng Y; Fest S; Kunert R; Katinger H; Pistoia V; Michon J; Lewis G; Ladenstein R; Lode HN
Mol Immunol; 2005 Jul; 42(11):1311-9. PubMed ID: 15950727
[TBL] [Abstract][Full Text] [Related]
3. On the optimal ratio of heavy to light chain genes for efficient recombinant antibody production by CHO cells.
Schlatter S; Stansfield SH; Dinnis DM; Racher AJ; Birch JR; James DC
Biotechnol Prog; 2005; 21(1):122-33. PubMed ID: 15903249
[TBL] [Abstract][Full Text] [Related]
4. Auditioning of CHO host cell lines using the artificial chromosome expression (ACE) technology.
Kennard ML; Goosney DL; Monteith D; Roe S; Fischer D; Mott J
Biotechnol Bioeng; 2009 Oct; 104(3):526-39. PubMed ID: 19544304
[TBL] [Abstract][Full Text] [Related]
5. Binding activities and antitumor properties of a new mouse/human chimeric antibody specific for GD2 ganglioside antigen.
Alvarez-Rueda N; Leprieur S; Clémenceau B; Supiot S; Sébille-Rivain V; Faivre-Chauvet A; Davodeau F; Paris F; Barbet J; Aubry J; Birklé S
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5613s-5620s. PubMed ID: 17875797
[TBL] [Abstract][Full Text] [Related]
6. Characterization of human IgG1 monoclonal antibody against gangliosides expressed on tumor cells.
Mukerjee S; Nasoff M; McKnight M; Glassy M
Hybridoma; 1998 Apr; 17(2):133-42. PubMed ID: 9627053
[TBL] [Abstract][Full Text] [Related]
7. Cleavage efficient 2A peptides for high level monoclonal antibody expression in CHO cells.
Chng J; Wang T; Nian R; Lau A; Hoi KM; Ho SC; Gagnon P; Bi X; Yang Y
MAbs; 2015; 7(2):403-12. PubMed ID: 25621616
[TBL] [Abstract][Full Text] [Related]
8. A comparative study of different vector designs for the mammalian expression of recombinant IgG antibodies.
Li J; Menzel C; Meier D; Zhang C; Dübel S; Jostock T
J Immunol Methods; 2007 Jan; 318(1-2):113-24. PubMed ID: 17161420
[TBL] [Abstract][Full Text] [Related]
9. A mechanistic understanding of production instability in CHO cell lines expressing recombinant monoclonal antibodies.
Kim M; O'Callaghan PM; Droms KA; James DC
Biotechnol Bioeng; 2011 Oct; 108(10):2434-46. PubMed ID: 21538334
[TBL] [Abstract][Full Text] [Related]
10. The generation of stable, high MAb expressing CHO cell lines based on the artificial chromosome expression (ACE) technology.
Kennard ML; Goosney DL; Monteith D; Zhang L; Moffat M; Fischer D; Mott J
Biotechnol Bioeng; 2009 Oct; 104(3):540-53. PubMed ID: 19557833
[TBL] [Abstract][Full Text] [Related]
11. Generation and Characterization of a Human/Mouse Chimeric GD2-Mimicking Anti-Idiotype Antibody Ganglidiximab for Active Immunotherapy against Neuroblastoma.
Eger C; Siebert N; Seidel D; Zumpe M; Jüttner M; Brandt S; Müller HP; Lode HN
PLoS One; 2016; 11(3):e0150479. PubMed ID: 26967324
[TBL] [Abstract][Full Text] [Related]
12. Chimeric anti-ganglioside GM2 antibody with antitumor activity.
Nakamura K; Koike M; Shitara K; Kuwana Y; Kiuragi K; Igarashi S; Hasegawa M; Hanai N
Cancer Res; 1994 Mar; 54(6):1511-6. PubMed ID: 8137257
[TBL] [Abstract][Full Text] [Related]
13. Expression of chimeric antibody in mammalian cells using dicistronic expression vector.
Xiong KH; Liang QC; Xiong H; Zou CX; Gao GD; Zhao ZW; Zhang H
Biotechnol Lett; 2005 Nov; 27(21):1713-7. PubMed ID: 16247680
[TBL] [Abstract][Full Text] [Related]
14. Validated detection of anti-GD2 antibody ch14.18/CHO in serum of neuroblastoma patients using anti-idiotype antibody ganglidiomab.
Siebert N; Seidel D; Eger C; Brackrock D; Reker D; Schmidt M; Lode HN
J Immunol Methods; 2013 Dec; 398-399():51-9. PubMed ID: 24055592
[TBL] [Abstract][Full Text] [Related]
15. DNA vaccine expressing the mimotope of GD2 ganglioside induces protective GD2 cross-reactive antibody responses.
Bolesta E; Kowalczyk A; Wierzbicki A; Rotkiewicz P; Bambach B; Tsao CY; Horwacik I; Kolinski A; Rokita H; Brecher M; Wang X; Ferrone S; Kozbor D
Cancer Res; 2005 Apr; 65(8):3410-8. PubMed ID: 15833876
[TBL] [Abstract][Full Text] [Related]
16. Stable microRNA expression enhances therapeutic antibody productivity of Chinese hamster ovary cells.
Strotbek M; Florin L; Koenitzer J; Tolstrup A; Kaufmann H; Hausser A; Olayioye MA
Metab Eng; 2013 Nov; 20():157-66. PubMed ID: 24144501
[TBL] [Abstract][Full Text] [Related]
17. Construction and characterization of a functional chimeric murine-human antibody directed against human fibrin fragment-D dimer.
Bulens F; Vandamme AM; Bernar H; Nelles L; Lijnen RH; Collen D
Eur J Biochem; 1991 Jan; 195(1):235-42. PubMed ID: 1899382
[TBL] [Abstract][Full Text] [Related]
18. Recombinant antibodies against ganglioside expressed on tumor cells.
Hanai N; Nakamura K; Shitara K
Cancer Chemother Pharmacol; 2000; 46 Suppl():S13-7. PubMed ID: 10950141
[TBL] [Abstract][Full Text] [Related]
19. New anti-GD2 monoclonal antibodies produced from gamma-interferon-treated neuroblastoma cells.
Gross N; Beck D; Portoukalian J; Favre S; Carrel S
Int J Cancer; 1989 Apr; 43(4):665-71. PubMed ID: 2467885
[TBL] [Abstract][Full Text] [Related]
20. [Construction of anti-human VEGF165 chimeric antibodies and expression in eukaryotic cells].
Ran Y; Yang Z; Wang G
Zhonghua Zhong Liu Za Zhi; 1999 Nov; 21(6):412-5. PubMed ID: 11776613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
